Cutaneous T-Cell Lymphoma

The FDA approved the novel immunotherapy denileukin diftitox-cxdl for treatment of certain patients with relapsed or refractory cutaneous T-cell lymphoma.

Healio has compiled April’s most-read news in dermatology.

A new study finds that dupilumab is associated with an increased risk for cutaneous T-cell lymphoma in patients taking the drug for atopic dermatitis.

The FDA announced several regulatory actions.

A greater proportion of patients with cutaneous T-cell lymphoma and sepsis were older, Black and experienced more sepsis episodes compared with patients with sepsis and a different type of non-Hodgkin lymphoma, according to a study.

The FDA placed a clinical hold on a phase 1 trial of LB1901, a chimeric antigen receptor T-cell therapy for treatment of adults with relapsed or refractory T-cell lymphoma.

Men with a prior cutaneous T-cell lymphoma were at increased risk for a second malignancy, according to a study.

Overall survival was lower for patients with early-stage cutaneous T-cell lymphoma who had low-level blood involvement, according to a study.

The FDA cleared an investigational new drug application for LB1901, a chimeric antigen receptor T-cell therapy in development for treatment of adults with relapsed or refractory T-cell lymphoma, according to the agent’s manufacturer.

Romidepsin combined with brentuximab vedotin was well-tolerated in patients requiring systemic therapy for cutaneous T-cell lymphoma, according to phase 1 data presented at ASH Annual Meeting and Exposition.